Immunosupressant Effect of the Extract of Tridax procumbens on Lymphocyte Cells Line from Patients with Systemic Lupus Erythematous: Immunoglobulin Gbiomarker
Keywords:
SLE, Tridax procumbens, immunoglobulin GAbstract
Systemic Lupus Erythematous (SLE) is one of the major autoimmune diseases that can cause severe damage to the tissues and organs in the body and lead to high mortality rates. The clinical manifestations are characterized by the production of autoantibody immunoglobulin G (Ig G) that fights component of the nucleus. The present scientific information issues about peculiar property of Tridax procumbens as immunosuppressant by inhibiting enzyme of cyclooxygenase-2 (COX-2) on surface of B cells. This study approved effect of the extract of Tridax procumbens on human lymphocytes cells line with SLE disease. The aim of this study was to approve effect of extract of Tridax procumbens in suppressing Ig G concentration from patient with stable SLE and patient with active SLE in vitro. This study was an in vitro experimental design on lymphocytes cell line that was isolated from whole blood patient with stable SLE and active SLE. Lymphocyte cells from healthy volunteer were also collected as control. American Rheumatism Association Diagnostic was used for inclusion criteria.Tridax procumbens was extracted with maceration method in solution of ethyl acetate. The extract was divided in several doses as immunosuppressant i.e.1000; 250; 62.5; 31.25; 15.13; and 3.91 µg/mL. Supernatant of the cultured cells was collected and examined for measuring Ig G concentration as secretion from activated B cells by ELISA. Ethical clearance had been completed before this study started. The extract of Tridax procumbens significantly suppressed Ig G secretion in patient with stable SLE at dose over 62.5 µg/mL, but Ig G concentration in patient with active SLE was significantly increased when compared with control. Furthermore from the analysis, effect of the Tridax procumbens extract on Ig G concentration followed dose dependent response. In in-vitro study, the extract of Tridax procumbens could significantly suppress Ig G secretion in healthy volunteer and patient with stable SLE. Otherwise, the extract does not suggest for patient with active SLE and it needs caution in use and investigation in-depth.
References
1.Renau AI ID. Male versus female lupus: a comparison of ethnicity, clinical features, serology and outcome over a 30 year period. Lupus. 2012;21(10):1041-8.
2.Radic M, Martinovic Kaliterna D RJ. Vascular manifestations of systemic lupus erythematosis. Neth J Med. 2013;71(1):10-6.
3.Erythematosus L. Diagnosis of Systemic Lupus Erythematosus. American
Family Physician. 2003;68(11):2179-86.
4.Djoerban Z. Pengobatan Penyakit Lupus Eritematosus Sistemik. Sub Bagian Hematologi, Bagian Ilmu Penyakit Dalam FKUI-RSCM. Jakarta; 2002.
5.Mok CC LC. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56(7):481-90.
6.Jachak SM, Gautam R, Selvam C, Madhan H, Srivastava A KT. Anti-inflammatory, cyclooxygenase inhibitory and antioxidant activities of standardized extracts of Tridax procumbens L.Fitoterapia. 2011;82(2):173-7.
7.Ismawan B. Herbal Indonesia Berkhasiat. Vol 08. Depok: PT Trubus Swadaya; 2010. p. 446-7.
8.Taddei A R-RA. Bioactivity studies of extracts from Tridax procumbens.
Phytomedicine. 2000;7(3):235-8.
9.Yaduvanshi B, Mathur R, Mathur SR VT. Evaluation of wound healing potential of topical formulation of leaf juice of tridax procumbens L. In mice. Indian J Pharm Sci. 2011;73(3):303-6.
10.Diwan PV, Tilloo LD KD. Steroid depressed wound healing and Tridax procumbens. Indian J Physiol Pharmacol. 1983;27(1):32-6.
11.Ryan EP, Pollock SJ, Pollack SJ, Murant TI, Bernstein SH, Felgar RE, et al.
Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. Journal of immunology. 2005 Mar 1;174(5):2619-26.
12.Press D. B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab. 2012;347-54.
13.Rantam FA. Metode Imunologi. Surabaya: Airlangga University Pers; 2003.
14.Bastian BC, Romisch J, Pâques EP BG. Lipocortins and phospholipases:new
aspects in the physiology of glucocorticosteroid effect. Hautarzt.1991;42(7):417-23.
15.Losy J, Michałowska-Wender G WM. The effect of large-dose prednisone therapy on IgG subclasses in multiple sclerosis. Acta Neurol Scand. 1994;89(1):69-71.
16.Smith HS. Aspirin-inspired analgesia: old drug, new mechanism, Sans Cox? Pain physician. 2012;15(4):E359-61.
17.Malaviya AN MM. Should low-dose aspirin also be a background therapy for all patients with systemic lupus erythematosus(SLE)?Lupus.2000;9(7):5612.
18.Caza TN, Talaber G PA. Metabolic regulation of organelle homeostasis in lupus T cells.Clin Immunol. 2012;144(3):200-13.
